Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where John Herbert Merrett is active.

Publication


Featured researches published by John Herbert Merrett.


Journal of Biological Chemistry | 2006

The Novel Nucleoside Analog R1479 (4′-Azidocytidine) Is a Potent Inhibitor of NS5B-dependent RNA Synthesis and Hepatitis C Virus Replication in Cell Culture

Klaus Klumpp; Vincent Leveque; Sophie Le Pogam; Han Ma; Wen-Rong Jiang; Hyunsoon Kang; Caroline Granycome; Margaret Singer; Carl Laxton; Julie Qi Hang; Keshab Sarma; David Bernard Smith; Dieter Heindl; Christopher John Hobbs; John Herbert Merrett; Julian A. Symons; Nick Cammack; Joseph Armstrong Martin; René Devos; Isabel Najera

Hepatitis C virus (HCV) polymerase activity is essential for HCV replication. Targeted screening of nucleoside analogs identified R1479 (4′-azidocytidine) as a specific inhibitor of HCV replication in the HCV subgenomic replicon system (IC50 = 1.28 μm) with similar potency compared with 2′-C-methylcytidine (IC50 = 1.13 μm). R1479 showed no effect on cell viability or proliferation of HCV replicon or Huh-7 cells at concentrations up to 2 mm. HCV replicon RNA could be fully cleared from replicon cells after prolonged incubation with R1479. The corresponding 5′-triphosphate derivative (R1479-TP) is a potent inhibitor of native HCV replicase isolated from replicon cells and of recombinant HCV polymerase (NS5B)-mediated RNA synthesis activity. R1479-TP inhibited RNA synthesis as a CTP-competitive inhibitor with a Ki of 40 nm. On an HCV RNA-derived template substrate (complementary internal ribosome entry site), R1479-TP showed similar potency of NS5B inhibition compared with 3′-dCTP. R1479-TP was incorporated into nascent RNA by HCV polymerase and reduced further elongation with similar efficiency compared with 3′-dCTP under the reaction conditions. The S282T point mutation in the coding sequence of NS5B confers resistance to inhibition by 2′-C-MeATP and other 2′-methyl-nucleotides. In contrast, the S282T mutation did not confer cross-resistance to R1479.


Chimia | 2003

Applications of Parallel Synthesis to Lead Optimization

Michael Altorfer; Philipp Ermert; Jürg Fässler; Saleem Farooq; Elke Maria Hillesheim; André Jeanguenat; Klaus Klumpp; Peter Maienfisch; Joseph Armstrong Martin; John Herbert Merrett; Kevin Edward Burdon Parkes; Jean-Pierre Obrecht; Thomas Pitterna; Daniel Obrecht

Parallel synthesis of focused compound libraries for hit confirmation and lead optimization are certainly important drivers for shortening the lead discovery phase in the pharmaceutical and crop protection industries. In this article we show with permission of Roche and Syngenta three real case studies where Polyphor synthesized focused libraries for lead validation and optimization using high-throughput parallel synthesis and purification techniques. The three examples differ significantly in the synthetic strategies which were employed as well as in the chemical complexity of the final products. A multigeneration approach towards insecticidal triazines, the application of a sequential three-component reaction towards insecticidal and fungicidal thiazoles and finally a multistep synthesis approach of advanced building blocks followed by a two-step final derivatization towards novel antiviral N-hydroxy-indolin-2-ones are presented. In all cases 100-200 analogues were synthesized using parallel synthesis in solution followed by purification of the final products by parallel flash or high-throughput (unattended) HPLC (coupled to MS) within four months. Promising biological results were obtained in all three cases.


Journal of Medicinal Chemistry | 2003

Use of a pharmacophore model to discover a new class of influenza endonuclease inhibitors.

Kevin Edward Burdon Parkes; Philipp Ermert; Jürg Fässler; Jane Ives; Joseph Armstrong Martin; John Herbert Merrett; Daniel Obrecht; Glyn Williams; Klaus Klumpp


Archive | 2009

4′-substituted nucleoside derivatives as inhibitors of HCV RNA replication.

René Devos; Christopher John Hobbs; Wen Rong Jiang; Joseph Armstrong Martin; John Herbert Merrett; Isabel Najera; Nobuo Shimma; Takuo Tsukuda


Archive | 2002

Anti-HCV nucleoside derivatives

René Devos; Christopher John Hobbs; Wen-Rong Jiang; Joseph Armstrong Martin; John Herbert Merrett; Isabel Najera


Journal of Medicinal Chemistry | 1990

Synthesis and antiviral activity of monofluoro and difluoro analogues of pyrimidine deoxyribonucleosides against human immunodeficiency virus (HIV-1).

Joseph Armstrong Martin; David J. Bushnell; Ian B. Duncan; Stephen J. Dunsdon; Michael J. Hall; Peter J. Machin; John Herbert Merrett; Kevin E. B. Parkes; Noel A. Roberts


Journal of Medicinal Chemistry | 1990

Synthesis and antiviral activity of metabolites of rimantadine

Percy S. Manchand; Richard L. Cerruti; Joseph Armstrong Martin; Christopher H. Hill; John Herbert Merrett; Elizabeth Keech; Robert B. Belshe; Edward V. Connell; Iain S. Sim


Archive | 2004

Anti-HIV pyrazole derivatives

Brian William Dymock; Philip Stephen Jones; John Herbert Merrett; Martin John Parratt


Archive | 2001

Anti-HIV imidazolone derivatives

Brian William Dymock; Philip Stephen Jones; John Herbert Merrett; Kevin Edward Burdon Parkes; Martin John Parratt; Daryl Simon Walter


Archive | 2009

Pharmaceutical compositions for treating diseases mediated by the hepatitis virus

Wen-Rong Jiang; Joseph Armstrong Martin; Nobuo Shimma; Takuo Tsukuda; René Devos; Christopher John Hobbs; John Herbert Merrett; Isabel Najera

Collaboration


Dive into the John Herbert Merrett's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Nobuo Shimma

Chugai Pharmaceutical Co.

View shared research outputs
Top Co-Authors

Avatar

Takuo Tsukuda

Chugai Pharmaceutical Co.

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge